CEO Eliane Schutte shared how Xeltis restorative devices can help combine clinical needs with a patient-centric approach in cardiovascular treatment. Speaking today at LSX World Congress 2022 in London, Eliane explained how the most advanced polymer-based restorative devices may offer clinical solutions that also help spare long waits for fistula maturation or reduce pain and bleeding from cannulation in hemodialysis, or eliminate painful vein harvesting for CABG procedures.
“Quality of life improvements that we see in trial experience are data points sometimes hard to quantify, but they are incredibly valuable when it comes to treatment acceptance or compliance,” explained Eliane to an audience of global medtech investors. “Dialysis nurses as part of our aXess trial, for instance, tell us how the lack of bleeding at puncturing or the shorter wait at session conclusion can literally change patients’ lives.”
Xeltis’ restorative devices are biocompatible and bioresorbable and are designed to embed patient’s tissue to fully transform into living vessels, rather than remaining an external body.
LSX World Congress gathers founders and CEOs of innovative start-ups through to publicly listed life science giants for peer-to-peer discussion, networking and partnering.
